CTNNB1 and adrenal cortex carcinoma: Nutlin-3a (RG7112), an MDM2 inhibitor, has shown efficacy in reducing tumor growth, inducing apoptosis, and inhibiting cellular proliferation and hormone production in ACC models, especially those with CTNNB1 mutations (57).